Introduction
============

Melanoma is the result of the malignant transformation of melanocytes. It accounts for approximately only 5% of all skin malignancies, but is thought to be the most invasive and lethal form ([@ref-11]). When compared with non-melanoma skin cancer, melanoma has higher invasiveness and a worse prognosis, and its incidence has increased significantly in recent years ([@ref-49]). The histopathological features of melanoma are not as distinguishing as its molecular heterogeneity, and its formation is based on the continuous alteration of specific genes and pathways that control metabolism or regulate key cellular functions ([@ref-40]). Although new treatments for melanoma are constantly being developed, their effectiveness is still unsatisfactory. If metastasis occurs, the results could be life-threatening, prompting clinicians to pursue new predictive markers and targeted therapeutic genes ([@ref-12]; [@ref-29]; [@ref-43]).

MicroRNAs (miRNAs) are small single-stranded non-coding RNAs with oncogenic or tumor-suppressive roles, consisting of 20--26 nucleotides. There is growing evidence that miRNAs play key roles in multiple developmental stages of human cancers, including cutaneous melanoma ([@ref-16]). These molecules can affect gene transcription by complementing the promoter region of a particular gene or by directly regulating the activity of a gene ([@ref-44]). miRNAs can even be released into the bloodstream by a tumor and can be detected in melanoma cells. Dysregulated miRNAs can also be used as survival markers in cutaneous melanoma patients ([@ref-47]), as seen in the signature of 18 miRNAs identified by [@ref-53] and the miRNAs identified by [@ref-4].

With the development of sequencing technology and various omics (genomics, transcriptomics, proteomics, etc.), a large amount of biological data have been acquired, leading to the development of bioinformatics to mine, utilize and integrate these data ([@ref-36]). Bioinformatics can be defined as the practical discipline of applying informatics technology (including applied mathematics, computer science and statistics) to understand and process biological tissue information related to macromolecules on a large scale ([@ref-34]). It has been applied in various fields of biological research, such as in the identification or diagnosis of disease biomarkers ([@ref-54]), individualized treatment of cancer, the preparation of tumor vaccines ([@ref-21]), among others. Various large public bioinformatics databases have been developed, such as the Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>) database, which is a functional genomics data repository that help users download experiments and curate gene expression profiles ([@ref-1]), and the Cancer Genome Atlas (TCGA, <https://portal.gdc.cancer.gov/>), which is the most useful tumor genomics program with at least 30 cancer types included ([@ref-5]). These two databases play a wide range of roles in the research of cancers including melanoma. For example, the data provided by GEO are used in the screening of melanoma prognostic factors ([@ref-20]; [@ref-57]). [@ref-48] conducted an in-depth analysis of UM (uveal melanoma) samples from TCGA project in order to gain a deeper understanding of the biological processes of UM tumors with distinct prognoses. Even anti-tumor drugs in melanoma patients with or without anti-PD-1 treatment have been analyzed using the GEO and TCGA databases ([@ref-56]).

Previous studies have shown that multiple miRNAs can be used as diagnostic and prognostic markers, but the number of cases is relatively small with inconsistent results ([@ref-25]; [@ref-49]). In our study, we screened microarray data from GEO, then downloaded the clinical information and expression profiles of cutaneous melanoma patients from TCGA. Our aim was to use bioinformatics methods on a large sample from TCGA database, evaluate the prognostic value of the differential expression of miRNAs (DEMs) by analyzing the high-throughput sequencing data, and establish a five-miRNA predictive signature of patient survival.

Materials & Methods
===================

Acquisition of a microarray data source and DEMs
------------------------------------------------

Variations in sample collection, storage, batch testing and detection platform methods can lead to data deviation, and so we could not simply directly combine different datasets. When selecting datasets, the inclusion criteria were: (1) datasets including more than 40 samples; (2) datasets with tumor tissue samples; and (3) datasets containing melanoma (including primary and metastatic melanoma) and pigmented nevi tissue simultaneously. Ultimately, [GSE35579](GSE35579) (cutaneous melanoma = 41, nevus = 11) was the one that met our requirements. After microarray data were downloaded from the GEO of the National Center for Biotechnology Information (NCBI), we preprocessed the miRNA expression data using the quantile normalized method, then identified DEMs between melanoma and benign nevi. The "limma" package in software R ([@ref-46]), which can be operated flexibly offline, was selected to process the differential expression data. *P* \< 0.05 was selected as the statistically significant cut-off criterion.

Identification of the relationship between DEMs and overall survival (OS) in melanoma patients
----------------------------------------------------------------------------------------------

DEMs obtained from the GEO database were matched in TCGA's database for further analysis of their relationship to patient prognosis. After removing patients without completed clinical information and with an OS (overall survival) time \<1 month, the remaining 428 patients were divided into high-risk and low-risk groups according to the median score of DEM expression level. We used 120 months as the end of our observation time, and patients with a survival period of more than 120 months were considered survivors. The DEM expression profiles acquired from TCGA, after being log2 transformed, were assessed with the Kaplan--Meier method and a log-rank test to preliminarily identify the miRNAs that were associated with patient survival. *P* \< 0.05 was considered to indicate statistically significant differences. Considering that multiple miRNAs have more reliable predictive effects, we used different combinations of several prognosis-related miRNAs to calculate the risk score for each melanoma patient in accordance with a high or low level of expression. Using this method, we classified the patients into two groups, high and low score groups, further using Kaplan--Meier analysis to assess these miRNA combinations. To make the experiment more objective, we only selected a meaningful combination of DEMs for follow-up study. The Kaplan--Meier results were visualized by the GraphPad Prism 5.0. Finally, univariate and multivariate Cox regression analyses were conducted to verify the prognostic role of the screened DEM signature.

Prediction of the DEM signature's target genes
----------------------------------------------

TargetScan (<http://www.targetscan.org/>), miRDB (<http://www.mirdb.org/>), DIANA (<http://www.microrna.gr/microT-CDS>), and miRmap (<https://mirmap.ezlab.org/app/>) were used to predict these candidate target genes. The FunRich (Functional enrichment analysis (<http://www.funrich.org/>) tool was used to intersect the results of the four prediction tools for further research.

Analysis of functions and pathways of target genes
--------------------------------------------------

GO term and KEGG pathway analysis was conducted on the overlapping terms in the Database for Annotation, Visualization and Integrated Discovery (DAVID, <https://david.ncifcrf.gov/home.jsp>) websites, providing a comprehensive set of functional annotation tools to help determine the biological meaning of the genes. The results were visualized by the R "ggplot2" package. A *P*-value \< 0.05 was set as the cut-off criterion.

Statistical analysis
--------------------

To compare the miRNA expression data between melanomas and nevi, we used unpaired *t*-tests. The relationship between expression data and the melanoma patients' clinical information was assessed with chi-square and *t*-tests. Kaplan--Meier survival analysis and univariate/multivariate Cox proportional hazard regression analyses were performed using IBM SPSS Statistics 25.0 to assess each DEM and miRNA signature prognostic function. A *P*-value \< 0.05 was considered statistically significant.

Results
=======

DEM identification and construction of a five-miRNA signature
-------------------------------------------------------------

We first acquired 185 (80 upregulated and 105 downregulated) differentially expressed miRNAs between melanomas (primary and metastatic) and benign nevi from the miRNA dataset [GSE35579](GSE35579), according to the standard of *P* \< 0.05. To make the results more intuitive, we used volcano maps ([Fig. 1](#fig-1){ref-type="fig"}) to show these DEMs. To find out whether differential miRNAs could distinguish a cancer sample from a nevus sample, we selected the top 100 miRNAs with the most obvious differences in expression to perform a hierarchic cluster heat map based on Euclidean distance (as shown in [Fig. 2](#fig-2){ref-type="fig"}), and the results were acceptable.

![Volcano maps.\
DEMs in [GSE35579](GSE35579) between melanoma and nevi: green represents down regulation in melanoma (logFC \< −1); red represents up regulation in melanoma (logFC \> 1); *P* \< 0.05.](peerj-07-7831-g001){#fig-1}

DEMs were matched in TCGA, and combined with the clinical information of melanoma patients (shown in [Table 1](#table-1){ref-type="table"}). DEMs that could not be found in TCGA were excluded, and each miRNA was analyzed to determine whether it was related to the prognoses. According to our statistical analysis, there were eight genes (miR-25, miR-100, miR-204, miR-211, miR-19b, miR-510, miR-511, miR-513c) closely related to the prognoses of the patients.

We integrated the expression of these eight miRNAs and applied different combinations calculating the risk score for each patient (the details of which can be found in the Methods section), and we found a very obvious prognostic significance when five of the miRNAs (miR-25, miR-204, miR-211, miR-510, miR-513c) were combined. Among these miRNAs, miR-204 correlated positively with prognosis, while miR-25, miR-211, miR-510, and miR-513c correlated negatively with prognosis. These details are listed in [Table 2](#table-2){ref-type="table"}. We then established a five-miRNA-based prognostic model. The prognostic characteristics of these five miRNAs are shown in [Fig. 2](#fig-2){ref-type="fig"} ([Figs. 3A](#fig-3){ref-type="fig"}--[3E](#fig-3){ref-type="fig"}). According to the median risk score, 428 patients were divided into a high-risk group (*n* = 222) and a low-risk group (*n* = 206). Survival analysis was performed using the Kaplan--Meier method with the log-rank test. The results showed that the survival rate of the high-risk group was significantly lower than that of the low-risk group (*P* = 0.001, [Fig. 3F](#fig-3){ref-type="fig"}). To explore whether these five miRNAs were related to clinical features, we conducted correlation analysis and found that, except for miR-25, these miRNAs might be related to T stage and Breslow depth value (see [Table 3](#table-3){ref-type="table"} for details).

Univariate and multivariate Cox regression analyses were used to test the effects of the five miRNA features (high-risk and low-risk) combined with the clinical features of melanoma patients (including age, T stage, N stage, M stage, and clinical stage) on OS (overall survival). Univariate analysis showed that T stage (HR = 0.443, *P* \< 0.000), N stage (HR = 0.517, *P* \< 0.000), clinical stage (HR = 0.543, *P* \< 0.000), age at diagnosis (HR = 1.563, *P* = 0.003), Breslow depth value (HR = 0.370, *P* \< 0.000) and the five-miRNA characteristics (HR = 0.613, *P* = 0.001) were associated with OS in melanoma patients. In the multivariate analysis, the five-miRNA characteristics (HR = 0.605, *P* = 0.006), N stage (HR = 0.246, *P* = 0.008) and Breslow depth value (HR = 0.509, *P* = 0.011) were all shown to be independent prognostic factors for patients with cutaneous melanoma ([Table 4](#table-4){ref-type="table"}).

![A hierarchic figure.\
Hierarchic analysis: green, black and red indicate the top 100 downregulated, nonsignificantly differentially expressed and up regulated DEMs, Respectively.](peerj-07-7831-g002){#fig-2}
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###### Clinical feature of melanoma patients from TCGA.

![](peerj-07-7831-g006)

  **Variables**           **Case, *n* (%)**
  ----------------------- -------------------
  Age at diagnosis (yr)   
  \<60                    241
  ≥60                     221
  NA                      8
  Gender                  
  Male                    290
  Female                  180
  T stage                 
  T0                      23
  T1 (*a* + *b*)          42
  T2 (*a* + *b*)          78
  T3 (*a* + *b*)          90
  T4 (*a* + *b*)          143
  Tis                     8
  TX                      47
  NA                      29
  Pathologic stage        
  Stage 0                 7
  Stage I                 77
  Stage II                140
  I/II NOS                14
  Stage III               171
  Stage IV                23
  NA                      38
  Node status             
  N0                      235
  N1--3                   178
  Nx                      36
  NA                      21
  Metastasis              
  M0                      418
  M1                      24
  NA                      28

**Notes.**

NANot available

10.7717/peerj.7831/table-2

###### The prognostic related differentially expressed miRNAs identifed between melanoma and nevi.

![](peerj-07-7831-g007)

  **Down-regulation DEMs**   ***P*-value**   **Up-regulation**   ***P*-value**
  -------------------------- --------------- ------------------- ---------------
  hsa-miR-211                0.033           hsa-miR-25          0.004
  hsa-miR-204                0.001                               
  hsa-miR-510                0.007                               
  hsa-miR-513c               0.014                               

**Notes.**

DEMsDifferentially expressed miRNAs

![Survival analysis and prognosis of cutaneous melanoma patients from TCGA.\
A--E show that the prognostic characteristics of these five miRNAs (miR-25, miR-204, miR-211, miR-510, miR-513c); F shows that the prognostic characteristics of a 5-miRNA signature (miR-25, miR-204, miR-211, miR-510, miR-513c). Blue curves represent the low expression group, and purple curves represent the high expression group.](peerj-07-7831-g003){#fig-3}
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###### Association between the five miRNAs and melanoma cancer clinical characters.

![](peerj-07-7831-g008)

  **Variables**              **miR-25 expression**         **miR-204 expression**         **miR-211 expression**                                               **miR-510 expression**         **miR-513c expression**                                                                                         
  -------------------------- ----------------------- ----- ------------------------ ----- ------------------------ ------------------------------------------- ------------------------ ----- ------------------------------------------- ----- ----- ------------------------------------------- ----- ----- -----------------------------------------
  Age                                                                                                                                                                                                                                                                                                         
  \<60                       124                     106   0.064                    92    138                      \<0.000[^\*^](#table-3fn1){ref-type="fn"}   122                      108   0.175                                       119   111   0.379                                       115   115   0.755
  ≥60                        89                      109                            118   80                                                                   92                       106                                               94    104                                               96    102   
  Gender                                                                                                                                                                                                                                                                                                      
  Female                     80                      81    0.980                    83    78                       0.424                                       73                       88    0.134                                       76    85    0.411                                       73    88    0.203
  Male                       133                     134                            127   140                                                                  141                      126                                               137   130                                               138   129   
  T stage                                                                                                                                                                                                                                                                                                     
  T1 + T2                    75                      62    0.157                    54    83                       0.004[^\*^](#table-3fn1){ref-type="fn"}     84                       53    \<0.000[^\*^](#table-3fn1){ref-type="fn"}   79    58    0.003[^\*^](#table-3fn1){ref-type="fn"}     75    62    0.037[^\*^](#table-3fn1){ref-type="fn"}
  T3 + T4                    103                     116                            121   98                                                                   89                       130                                               91    128                                               95    124   
  Lymph node status                                                                                                                                                                                                                                                                                           
  N0                         106                     108   0.758                    107   107                      0.955                                       107                      107   0.955                                       109   105   0.811                                       103   111   0.516
  N1--2                      82                      89                             86    85                                                                   85                       86                                                85    86                                                88    83    
  Mestasis                                                                                                                                                                                                                                                                                                    
  M0                         192                     193   0.841                    189   196                      0.769                                       188                      197   0.243                                       193   192   0.823                                       188   197   0.458
  M1                         10                      11                             11    10                                                                   13                       8                                                 10    11                                                12    9     
  Clinical stage                                                                                                                                                                                                                                                                                              
  I + II                     107                     95    0.166                    102   100                      0.715                                       97                       105   0.512                                       97    105   0.738                                       93    109   0.250
  III + IV                   84                      99                             89    94                                                                   94                       89                                                91    92                                                95    88    
  Breslow depth value (mm)                                                                                                                                                                                                                                                                                    
  \<3                        83                      77    0.255                    70    90                       0.041[^\*^](#table-3fn1){ref-type="fn"}     91                       69    \<0.000[^\*^](#table-3fn1){ref-type="fn"}   91    69    \<0.000[^\*^](#table-3fn1){ref-type="fn"}   84    76    0.015[^\*^](#table-3fn1){ref-type="fn"}
  ≥3                         78                      93                             94    77                                                                   61                       110                                               61    110                                               67    104   

**Notes.**

*P* \< 0.05 was considered statistically significant.

10.7717/peerj.7831/table-4

###### TCGA univariable and multivariable Cox regression analysis.

![](peerj-07-7831-g009)

  Variables                                       Univariate analysis    Multivariate analysis                                              
  ----------------------------------------------- ---------------------- ------------------------------------------- ---------------------- -----------------------------------------
  Age at diagnosis (≥60 vs. \<60)                 1.563 (1.166--2.096)   0.003[^\*^](#table-4fn1){ref-type="fn"}     1.199(0.839--1.714)    0.319
  T stage (T3 + T4 vs. T1 + T2)                   0.443(0 .316-0.622)    \<0.000[^\*^](#table-4fn1){ref-type="fn"}   0.825(0.468--1.456)    0.507
  N stage (N1--2 vs. N0)                          0.517(0.380--0.703)    \<0.000[^\*^](#table-4fn1){ref-type="fn"}   0.246(0.087--0.699)    0.008[^\*^](#table-4fn1){ref-type="fn"}
  M stage (M1 vs. M0)                             0.554(0.292--1.051)    0.071                                       0.616(0.218--1.741)    0.361
  Clinical stage (III + IV vs. I + II)            0.543(0.399--0.738)    \<0.000[^\*^](#table-4fn1){ref-type="fn"}   1.986(0.691--5.708)    0.203
  Gender (Male vs. Female)                        0.997(0.734--1.355)    0.986                                       1.040 (0.726--1.491)   0.830
  Breslow depth value (≥3 mm vs. \<3 mm)          0.370(0.265--0.518)    \<0.000[^\*^](#table-4fn1){ref-type="fn"}   0.509(0.302--0.859)    0.011[^\*^](#table-4fn1){ref-type="fn"}
  Five-miRNA signature (high risk vs. low risk)   0.613(0.456--0.823)    0.001[^\*^](#table-4fn1){ref-type="fn"}     0.605(0.424--0.863)    0.006[^\*^](#table-4fn1){ref-type="fn"}

**Notes.**

*P* \< 0.05 was considered statistically significant.

GO and KEGG pathway analysis of target genes of the five-miRNA signature
------------------------------------------------------------------------

Using TargetScan, miRDB, DIANA, and miRmap, we predicted five miRNA target genes (miR-25, miR-204, miR-211, miR-510, and miR-513c). The four prediction tools' intersecting genes were visualized using the FunRich tool ([Figs. 4A](#fig-4){ref-type="fig"}--[4E](#fig-4){ref-type="fig"}). A total of 367 (228 miR-25, 28 miR-204, 31 miR-211,77 miR-510, 37 miR-513c, and deleted duplicate values) overlapping genes were entered into DAVID, and assessed by GO and KEGG pathway analyses. The biological process (BP) analysis results showed that the genes were concentrated in the transcription regulation, angiogenesis, protein phosphorylation and ubiquitination ([Fig. 5A](#fig-5){ref-type="fig"}). Cellular component (CC) analysis showed that these genes were concentrated in the cytoplasm, nucleus, focal adhesion and cell--cell adherens junctions ([Fig. 5B](#fig-5){ref-type="fig"}). Molecular function (MF) analysis showed that genes were concentrated in protein binding and ubiquitin-protein transferase activity ([Fig. 5C](#fig-5){ref-type="fig"}). KEGG pathway analysis showed that these genes were concentrated in the PI3K-Akt signaling pathway, ubiquitin-mediated proteolysis, and focal adhesion pathway ([Fig. 5D](#fig-5){ref-type="fig"}).

![Venn diagrams.\
Target genes of the five DEMs were identified by four software programs, including TargetScan, miRDB, DIANA and miRmap, to acquire overlapping genes by the Funrich tool. (A) miR-25, (B) MiR-204, (C) MiR-211, (D) miR-510, (E) miR-513c.](peerj-07-7831-g004){#fig-4}

![GO and KEGG pathway analyses.\
(A) The biological process (BP) analysis; (B) cellular component (CC) analysis; (C) molecular function (MF) analysis; (D) KEGG pathway analysis.](peerj-07-7831-g005){#fig-5}

Discussion
==========

The melanocyte pedigree is derived from the neural ridge, originating in the neural tube, and these cells migrate to specific locations in the skin , hair follicle and other parts of the body during embryonic development. In patients with vitiligo, the pigment "island" appears first in a location around the hair follicles after UVB treatment, which suggests that melanocytes have stem cell properties. These characteristics may contribute to the melanoma-derived invasion ([@ref-38]). Caucasian populations have had a stable CM mortality rate since the 1990s, while the age-standardized mortality rate of cutaneous melanoma patients in East Asian populations has significantly increased over the past six decades ([@ref-7]). As the aging population grows, the incidence of melanoma is predicted to also increase ([@ref-27]). Early detection and initial care are still crucial for treatment ([@ref-52]). Recent studies have shown that epigenetic mechanisms play a very complex role in the development and progression of melanoma, including its methylation, chromosomal changes and remodeling, and regulation of the active function of various non-coding RNAs ([@ref-51]). Research on microRNAs is more developed compared to that of other non-coding RNAs, and these molecules play a significant role in nearly every biological process in nevi and melanomas, including proliferation, invasion, and apoptosis. Because of their chemical stability, these molecules can resist the degradation of RNase and can distinguish between different types of cancers, specifically those that can be secreted into the serum by tumor cells. Therefore, these molecules can be used to predict the prognosis and to perform the initial diagnosis in melanoma patients ([@ref-49]). Previous studies have explored the relationship between miRNAs and the prognoses of melanoma patients, but these studies were usually small sample studies without uniform results, that only looked at the primary melanoma or metastatic stage of the tumor, and only focused on single miRNAs ([@ref-14]; [@ref-25]; [@ref-50]). TCGA's database contains an abundance of cancer information, making access to cancer expression profile data easy and cost-effective. However, unlike for other cancers, TCGA's database only contains skin melanoma samples without normal control tissue nor nevi tissue information, and we were unable to obtain differentially expressed miRNAs. Thus, we obtained the DEMs from the GEO database, performed prognostic analysis on the DEMs with expression profiles and clinical information sourced from TCGA's database, and gained eight prognosis-associated miRNAs. Considering that the main purpose of our experiment was to create a multi-gene-based reliable prognostic signature, and the different combinations of these miRNAs were not all meaningful, we will only discuss the five-miRNA signature that can be used as a prognostic factor to make our results more clear and purposeful. Through additional analysis, we established a five-miRNA (miR-25, miR-204, miR-211, miR-510, miR-513c) signature to make the results more reliable. This five-miRNA based signature associated with the prognosis of cutaneous malignant melanoma will provide a theoretical basis for later studies, and can be used to non-invasively predict clinical prognoses in melanoma patients.

We used previous miRNA studies to verify the reliability of our results. In our study, miRNA-25 was the sole upregulated microRNA of the five miRNAs. [@ref-60] found that miRNA-25 can be secreted into serum and can be used as a marker for the early diagnosis of gastric cancer. [@ref-28] found that miRNA-25 directly regulates P57 (a tumor suppressor gene), and the abnormal expression of this miRNA in gastric cancer patients can advance cancer cells from G1 to S phase. [@ref-32] tested the serum of patients with pancreatic cancer and found that miRNA-25 levels were considerably higher than that of the normal control group, indicating that miRNA-25 can be used in the prognosis of pancreatic cancer. Zoni et al. observed that miR-25 is a key regulator of human prostate cancer invasiveness, and that it interacts directly with *α*(v)---and *α*(6)---integrins. Interestingly, [@ref-61] also found that miR-25 was a tumor suppressor in highly aggressive prostate cancer. [@ref-22] found that the expression of miR-25 increased in melanoma tissue and melanocyte cell lines, and promoted melanoma cell proliferation and invasion, in part, by targeting Dickkopf-associated protein 3 (DKK3). This result is consistent with the poorer prognosis in melanoma patients with increased miRNA-25 expression. In our experiments, miRNA-204 was expressed at low levels in melanoma cells, and K-M survival analysis showed that the higher the expression, the longer the OS time. This finding is consistent with previous studies, such as Xin Chen et al.'s mechanistic study on the LINC01234-miR-204-5p-CBFB axis in gastric cancer patients where miR-204 was found to have low expression in gastric cancer tissues. In a gastric cancer cell miR-204 over exposure assay, miR-204 was found to inhibit the proliferation of cancer cells and to induce apoptosis and cell cycle arrest in G1-G0 phase, and survival analysis showed that patients with higher miR-204 levels had a better prognosis ([@ref-6]). In studies of colorectal cancer, nasopharyngeal carcinoma, and melanoma, miRNA-204 was suggested to have an inhibitory effect on cancer cells and to possibly be associated with cancer cell resistance or anti-radiation mechanisms ([@ref-3]; [@ref-10]; [@ref-33]). Marco et al. suggested that the low expression or loss of miR-204 play a key role in the progression of melanoma. In this study, miR-204 was associated with a better prognosis in cutaneous melanoma patients ([@ref-14]). Previously published studies and data from existing miRNA databases indicate that miR-204-5p and miR-211-5p share some common targets, and, as a matter of fact, miR-204 and miR-211 have very similar nuclear targets. The nucleotide sequence has only two different nucleotides in the entire sequence and in the same seed region, which may be why these molecules share some common targets. In preceding studies, these miRNAs acted as tumor suppressors in melanoma and inhibited cell invasion ([@ref-10]; [@ref-30]). The most important function of miR-211 is the direct or indirect targeting of many other genes that may affect melanoma invasiveness and adhesion ([@ref-2]). In our study, both miR-204 and miR-211 were down regulated in melanoma tissues, but miR-204 was positively associated with tumor progression , miR-211 showed the opposite results. This result may be due to the small sample size of the GEO data set we selected. The reason for this situation needs further exploration. Early research of miR-510 did not examine its relationship with cancer, only its aberrant expression in irritable bowel syndrome ([@ref-26]). Researchers later discovered its relationship to cancer; for example, [@ref-41] found that miR-510 can predict the survival of patients with local stage I non-small cell lung cancer after surgical resection. miR-510 also plays a role in promoting tumor growth and invasion in breast cancer ([@ref-17]). In our study, we found that the higher the expression of miR-510, the poorer the prognoses of melanoma patients. [@ref-35] proposed that the expression of miR-513c in pulmonary neuroendocrine tumors was involved in tumor grade, and [@ref-55] studied African-American patients with prostate cancer and acquired similar results. Previous studies also included miR-513c in the establishment of a nine-miRNA based uveal melanoma prognostic model ([@ref-57]). However, we missed including a related study on the mechanism of action of miR-510 and miR-513c in cutaneous melanoma.

To further verify the active mechanisms of these five miRNAs, we performed miRNA target gene predictions and found a total of 367 overlapping target genes. Interestingly, 222 of them were target genes derived from miR-25 (mainly enriched in the PI3K-Akt signaling pathway), 77 were target genes derived from miR-510 (mainly enriched in ubiquitin-mediated proteolysis), and the few remaining genes were target genes of other miRNAs. KEGG pathway analysis revealed that these target genes were mainly involved in the PI3K-Akt pathway, ubiquitin-mediated proteolysis, and cell adhesion. The most abundant genes, including PHLPP2, SGK3, CREB5, COL5A3, PTEN, ITGA5, ITGAV, COL27A1, CREB3L2, COL1A2, PPP2R5E, PIK3AP1, GNG2, and PIK3R3, were enriched in the PI3K-Akt pathway. The PI3K-Akt pathway (phosphoinositide 3-kinase-RAC-alpha serine/threonine-protein kinase) is involved in a variety of cellular processes in both normal cells and cancer cells, including cell survival, metabolism, transmigration, and proliferation ([@ref-52]). For example, abnormal PI3K-Akt-mTOR signaling is one of the most common dysfunctions present in human cancers ([@ref-24]). The use of PI3K-Akt as a target in the treatment of cancer has been extensively researched ([@ref-19]). Phosphatase and tensin homolog (PTEN), a tumor suppressor gene, has been the focus of many studies. PI3K-Akt-PTEN signaling has been confirmed in previous studies of breast cancer and prostate cancer ([@ref-23]; [@ref-52]; [@ref-58]). In cutaneous melanoma, PTEN is downregulated, and this type of PTEN loss can increase T cell-mediated immunotherapy resistance ([@ref-42]). In our study, we showed that miR-25 may promote the development of cutaneous melanoma by downregulating the expression of PTEN, thus affecting the prognoses of melanoma patients. Feng et al. increased the sensitivity of hepatoma stem cells to TRAIL (Tumor necrosis factor (TNF) -related apoptosis-inducing ligand), reducing apoptosis by knocking out miR-25. This effect is also achieved through the PTEN/PI3K/Akt signal pathway ([@ref-13]). The adhesion-related genes obtained by KEGG analysis included ACTB, ITGA5, ITGAV, COL27A1, COL1A2, RAP1B, SHC1, COL5A3, PIK3R3, PPP1CC, and PTEN, and we found that most of these genes were also involved in the PI3K signaling pathway. Degradation of the basement membrane and the extracellular matrix (ECM) is critical for the invasion and metastasis of malignant cells. ECM ligands not only control cell adhesion, migration, and actin cytoskeleton structure through signaling pathways, but they also control anchorage dependence, a key group of survival mechanisms ([@ref-9]; [@ref-39]). While COL27A1, COL1A2, and COL5A3 are encoded ECM components, experiments have found that the upregulation of COL1A2 in cancer can serve as a molecular basis for metastasis development ([@ref-31]). Integrins are the major cell-adhesive receptor; are key components of signaling molecules, mechanical transducers, and cellular migration mechanisms; and are involved in many aspects ranging from primary tumor to metastatic cancer progression ([@ref-18]) Integrin-alpha-5 (ITGA5) and integrin-alpha-V (ITGAV) are members of the integrin receptor gene family, closely related to the regulation of cancer growth and metastasis ([@ref-8]; [@ref-37]). Ubiquitination is a widespread post-transcriptional modification, a selective marker that binds to protein aggregates and dysfunctional organelles, thereby promoting autophagy-dependent degradation. Autophagy can promote the growth of tumor cells by maintaining arginine-serine circulation ([@ref-15]; [@ref-45]). [@ref-59] showed that ubiquitin-mediated proteolysis by bioinformatics analysis may have potential as a prognostic and predictive marker for survival in patients with uveal melanoma.

In summary, the five screened miRNAs and their target genes were closely related to the occurrence and development of tumors, and the results proved reliable. Our established five-miRNA signature theoretically predicted the survival of melanoma patients, but further experiments are needed to determine the mode of action and mechanism of these miRNAs, and whether they can be used in a non-invasive diagnostic method.

Conclusion
==========

The five screened miRNAs and their target genes were closely related to the occurrence and development of tumors, and the results proved reliable. The identified five-miRNA signature may serve as a prognostic biomarker, or even as a potential therapeutic target, in cutaneous melanoma patients.
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###### Multiple datasets from TCGA, GEO, and DAVID were used to determine the relationship between differentially expressed miRNAs and melanoma prognosis

\(A\) The data in folder A is downloaded from GEO GSE35579 and used to screen for differentially expressed genes in melanoma and nevi. (B) The data in folder B was downloaded from TCGA to obtain miRNA expression profiles and clinical features of melanoma patients. (C) The data in folder C is used to demonstrate the process of determining the relationship between the expression of differentially expressed genes and the clinical features of melanoma patients. (D) The data in folder D shows how to determine the prognostic relationship between five differentially expressed miRNAs and melanoma patients by SPSS software. (E) The data in folder E is downloaded from DAVID, which is used to perform miRNAs target gene GO and KEGG analysis.

###### 

Click here for additional data file.

We thank Chen Zhang, Yaling Li, and Xiaoqing Jian for their support over the past years.

miRNAs

:   microRNAs

DEMs

:   the differential expression of miRNAs

GEO

:   Gene Expression Omnibus

TCGA

:   The Cancer Genome Atlas

UM

:   Uveal Melanoma

DAVID

:   The Database for Annotation, Visualization and Integrated Discovery

GO

:   Gene Ontology

OS

:   overall survival

HR

:   hazard ratio

PI3K-Akt

:   phosphoinositide 3-kinase-RAC-alpha serine/threonine-protein kinase

CM

:   cutaneous melanoma

ECM

:   extracellular matrix
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